40 mg (N = 3) | 80 mg (N= 39) | 160 mg (N = 73) | 240 mg (N = 76) | 360 mg (N = 3) | 480 mg (N = 3) | Total (N = 197) | |
---|---|---|---|---|---|---|---|
Age, years | |||||||
Median | 68 | 68 | 67 | 66 | 66 | 63 | 67 |
Range | 66-77 | 45-80 | 54-80 | 49-79 | 66-79 | 58-71 | 45-80 |
ECOG performance status | |||||||
0 | 2 (66.7) | 13 (33.3) | 20 (27.4) | 26 (34.2) | 0 | 0 | 61 (31.0) |
1 | 1 (33.3) | 26 (66.7) | 53 (72.6) | 50 (65.8) | 3 (100) | 3 (100) | 136 (69.0) |
Gleason score | |||||||
<9 | 2 (66.7) | 18 (46.2) | 43 (58.9) | 34 (44.7) | 1 (33.3) | 2 (66.7) | 100 (50.8) |
≥9 | 1 (33.3) | 14 (35.9) | 28 (38.4) | 37 (48.7) | 1 (33.3) | 1 (33.3) | 82 (41.6) |
Unknown | 0 | 7 (17.9) | 2 (2.7) | 5 (6.6) | 1 (33.3) | 0 | 15 (7.6) |
PSA (ng/mL) | |||||||
Median | 34.3 | 70.6 | 73.7 | 62.2 | 112.7 | 21.5 | 66.1 |
Range | 9.7-36.8 | 2.7-2384.0 | 3.7-4796.0 | 3.3-3382.0 | 19.7-757.8 | 11.0-96.5 | 2.7-4796.0 |
Alkaline phosphatase | |||||||
Normal | 3 (100) | 28 (71.8) | 56 (76.7) | 43 (56.6) | 1 (33.3) | 2 (66.7) | 133 (67.5) |
Abnormal | 0 | 11 (28.2) | 17 (23.3) | 33 (43.4) | 2 (66.7) | 1 (33.3) | 64 (32.5) |
Number of bone metastases | |||||||
≤5 | 1 (33.3) | 12 (30.8) | 23 (31.5) | 24 (31.6) | 1 (33.3) | 1 (33.3) | 62 (31.5) |
>5 | 2 (66.7) | 27 (69.2) | 50 (68.5) | 52 (68.4) | 2 (66.7) | 2 (66.7) | 135 (68.5) |
Visceral metastases* | |||||||
Yes | 0 | 6 (15.4) | 13 (17.8) | 15 (19.7) | 1 (33.3) | 1 (33.3) | 36 (18.3) |
No | 3 (100) | 33 (84.6) | 60 (82.2) | 61 (80.3) | 2 (66.7) | 2 (66.7) | 161 (81.7) |
Prior treatment | |||||||
Surgery of primary tumor | 2 (66.7) | 12 (30.8) | 24 (32.9) | 19 (25.0) | 0 | 1 (33.3) | 58 (29.4) |
Chemotherapy | 0 | 19 (48.7) | 29 (39.7) | 32 (42.1) | 0 | 2 (66.7) | 82 (41.6) |
Radiotherapy | 1 (33.3) | 12 (30.8) | 18 (24.7) | 18 (23.7) | 0 | 1 (33.3) | 50 (25.4) |